The GPANK1 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma epithelial cell line. This product provides a loss-of-function model for GPANK1, achieved through CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool of cells with targeted modifications at the GPANK1 locus. The polyclonal format preserves the genetic diversity inherent to the knockout population, enabling robust functional studies without the clonal selection bias associated with monoclonal cell lines.
The parental NCI-H1975 cell line is a widely employed non-small cell lung cancer (NSCLC) model originating from a female patient with lung adenocarcinoma. These cells harbor the EGFR L858R mutation, rendering them sensitive to EGFR tyrosine kinase inhibitors and providing a relevant platform for investigating oncogenic signaling, tumor progression, and therapeutic resistance mechanisms. The NCI-H1975 background is particularly suited for dissecting molecular pathways that influence drug sensitivity and tumor cell survival in EGFR-mutant NSCLC.
GPANK1 encodes a G-patch and ankyrin repeat domain-containing protein that functions as a component of the spliceosome, where it facilitates pre-mRNA splicing. This nuclear protein interacts with core spliceosomal factors, including PRPF8, PRPF6, and SNRNP200, and is implicated in the assembly and activity of the U5 snRNP. Through these interactions, GPANK1 influences the alternative splicing of transcripts involved in cell cycle regulation and cell survival. While upstream regulators of GPANK1 remain poorly defined, its disruption is expected to perturb spliceosome dynamics, leading to aberrant splicing patterns that may affect the expression of cell cycle regulators and other downstream targets.
In the NCI-H1975 lung adenocarcinoma context, loss of GPANK1 may compromise spliceosome integrity and deregulate mRNA processing, potentially altering cell proliferation and viability. This polyclonal knockout model enables the systematic study of splicing-dependent cellular processes in EGFR-mutant NSCLC, offering a tool to identify novel vulnerabilities associated with alternative splicing defects. Given the critical role of the spliceosome in cancer biology, GPANK1 knockout cells can help elucidate how splicing factor alterations contribute to tumor maintenance and drug response.
Typical research applications include investigating the impact of splicing dysregulation on lung cancer pathogenesis, identifying spliceosome-dependent therapeutic targets, and exploring mechanisms of resistance to EGFR inhibitors. Representative assays such as RNA-seq for alternative splicing analysis, RT-qPCR for splicing isoform quantification, and Western blotting for spliceosomal proteins can be employed. Additionally, cell viability and drug sensitivity assays with EGFR inhibitors, coupled with flow cytometric cell cycle profiling, allow functional characterization of GPANK1 loss. For further information or technical support, please contact Ascent Research.
